1
|
Su R, Chen G, Yan L, Liu W, Zhao S, Dai Q, Yuan S, Shen X, Yu W, Gong X, Yu M. Biological evaluation of a novel bilirubin adsorbent and its therapeutic effect on animal models of hyperbilirubinemia. J Biomed Mater Res B Appl Biomater 2021; 110:828-837. [PMID: 34767679 DOI: 10.1002/jbm.b.34963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Revised: 10/13/2021] [Accepted: 10/29/2021] [Indexed: 11/05/2022]
Abstract
Hyperbilirubinemia caused severe hepatobiliary diseases with various causes, especially hepatic fibrosis and cirrhosis caused by end-stage hepatitis B and C. Plasma adsorption perfusion (PP) has a tremendous advantage in treating patients with hyperbilirubinemia and liver failure, wherein, a safe and effective adsorbent is the key to filter out bilirubin successfully in PP. In this work, a simple engineering strategy, a new porous polymer adsorption resin ERM-0100 based on the homopolymer predispersion system, is proposed to produce high-performance bilirubin adsorbents. Preliminary experimental results show that ERM-0100 exhibits a large surface area and uniformly porous structure. Experimental results verify that ERM-0100 has high biocompatibility and bilirubin adsorption efficiency (TBIL:35%, direct bilirubin [DBIL]:30%, IBIL:87%) that is significantly higher than most of the reported adsorbents. Animal experiments prove that ERM-0100 has high bilirubin adsorption efficiency and can improve the liver function of animals. The combination of high biocompatibility and high adsorption capacity positions the ERM-0100 as a promising candidate for bilirubin removal.
Collapse
Affiliation(s)
- Rui Su
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China.,Tianjin Institute of Hepatology, Medical Bioengineering Laboratory, Tianjin, China
| | - Guanming Chen
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China
| | - Lihua Yan
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China.,Tianjin Institute of Hepatology, Medical Bioengineering Laboratory, Tianjin, China
| | - Wei Liu
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China.,Tianjin Institute of Hepatology, Medical Bioengineering Laboratory, Tianjin, China
| | - Shengjiang Zhao
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China
| | - Qinghai Dai
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China.,Tianjin Institute of Hepatology, Medical Bioengineering Laboratory, Tianjin, China
| | - Shi Yuan
- Tianjin First Central Hospital, Animal Laboratory Center, Tianjin, China
| | - Xiaomin Shen
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China
| | - Wanyou Yu
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China
| | - Xiaojie Gong
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China
| | - Meili Yu
- Tianjin City Second People's Hospital, Hepatology Department, Tianjin, China.,Tianjin Institute of Hepatology, Medical Bioengineering Laboratory, Tianjin, China
| |
Collapse
|
2
|
Donati G, Angeletti A, Gasperoni L, Piscaglia F, Croci Chiocchini AL, Scrivo A, Natali T, Ullo I, Guglielmo C, Simoni P, Mancini R, Bolondi L, La Manna G. Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). J Nephrol 2020; 34:77-88. [PMID: 32710265 PMCID: PMC7881965 DOI: 10.1007/s40620-020-00799-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2020] [Accepted: 07/04/2020] [Indexed: 01/15/2023]
Abstract
Background CPFA is an extracorporeal treatment used in severe sepsis to remove circulating proinflammatory cytokines. Limited evidence exists on the effectiveness of bilirubin adsorption by the hydrophobic styrenic resin, the distinctive part of CPFA. The aim of this study is to validate CPFA effectiveness in liver detoxification. Methods In this prospective observational study, we enrolled patients with acute or acute-on-chronic liver failure (serum total bilirubin > 20 mg/dL or MELD Score > 20) hospitalized from June 2013 to November 2017. CPFA was performed using the Lynda (Bellco/MedTronic, Mirandola, Italy) or the Amplya (Bellco/MedTronic, Mirandola, Italy) machines. Anticoagulation was provided with unfractionated heparin or citrate. Bilirubin and bile acids reduction ratios per session (RRs) were the main parameters for hepatic detoxification. Results Twelve patients with acute (n = 3) or acute-on-chronic (n = 9) liver failure were enrolled. Alcohol was the main cause of liver disease. Thirty-one CPFA treatments of 6 h each were performed, 19 with heparin and 12 with citrate. RRs was 28.8% (range 2.2–40.5) for total bilirubin, 32.7% (range 8.3–48.9) for direct bilirubin, 29.5% (range 6.5–65.4) for indirect bilirubin and 28.9% (16.7- 59.7) for bile acids. One patient received liver transplantation and 8/9 were alive at 1 year of follow-up. Three patients (25%) died: 2 during hospitalization and 1 for a cardiac event at 4 months of follow up with restored liver function. Conclusions CPFA resulted to be effective in liver detoxification. Thus, it may be considered as a “bridge technique” both to the liver transplant and to the recovery of the basal liver function.
Collapse
Affiliation(s)
- Gabriele Donati
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy
| | - Andrea Angeletti
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy
| | - Lorenzo Gasperoni
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy
| | - Fabio Piscaglia
- Internal Medicine Unit, S. Orsola Hospital, University of Bologna, Bologna, Italy
| | - Anna Laura Croci Chiocchini
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy
| | - Anna Scrivo
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy
| | - Teresa Natali
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy
| | - Ines Ullo
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy
| | - Chiara Guglielmo
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy
| | - Patrizia Simoni
- Laboratory of Gastroenterology, S. Orsola Hospital, University of Bologna, Bologna, Italy
| | - Rita Mancini
- Metropolitan Laboratory, S. Orsola Hospital, University of Bologna, Bologna, Italy
| | - Luigi Bolondi
- Internal Medicine Unit, S. Orsola Hospital, University of Bologna, Bologna, Italy
| | - Gaetano La Manna
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplantation Unit, S. Orsola Hospital, University of Bologna, Via G. Massarenti 9 (Pad. 15), 40138, Bologna, Italy.
| |
Collapse
|
3
|
Li Q, Zhao W, Guo H, Yang J, Zhang J, Liu M, Xu T, Chen Y, Zhang L. Metal-Organic Framework Traps with Record-High Bilirubin Removal Capacity for Hemoperfusion Therapy. ACS APPLIED MATERIALS & INTERFACES 2020; 12:25546-25556. [PMID: 32393019 DOI: 10.1021/acsami.0c03859] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Adsorption-based hemoperfusion has been widely used to remove toxins from the blood of patients suffering acute liver failure (ALF). However, its detoxification effect has been severely hampered by the unsatisfactory adsorption performance of clinically used porous adsorbents, such as activated carbon (AC) and adsorption resin. Herein, two cage-based metal-organic frameworks (MOFs), PCN-333 (constructed from 4,4,4-s-triazine-2,4,6-triyl-tribenzoic acid (H3TATB) ligands and Al3 metal clusters) and MOF-808 (constructed from 1,3,5-benzenetricarboxylic acid (H3BTC) ligands and Zr6 metal clusters), are introduced for highly efficient hemoperfusion. They possess negligible hemolytic activity and can act as "bilirubin traps" to achieve outstanding adsorption performance toward bilirubin, a typical toxin related to ALF. Notably, PCN-333 shows a record-high adsorption capacity (∼1003.8 mg g-1) among various bilirubin adsorbents previously reported. More importantly, they can efficiently adsorb bilirubin in bovine serum albumin (BSA) solution or even in 100% fetal bovine serum (FBS) due to their high selectivity. Strikingly, the adsorption rate and capacity of PCN-333 in biological solutions are approximately four times faster and 69 times higher than those of clinical AC, respectively. Findings in this work pave a new avenue to overcome the challenge of low adsorption efficiency and capacity in hemoperfusion therapy.
Collapse
Affiliation(s)
- Qingsi Li
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| | - Weiqiang Zhao
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| | - Hongshuang Guo
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| | - Jing Yang
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| | - Jiamin Zhang
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| | - Min Liu
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| | - Tong Xu
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| | - Yisheng Chen
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| | - Lei Zhang
- Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China
- Qingdao Institute for Marine Technology of Tianjin University, Qingdao, Shandong 266235, China
| |
Collapse
|
4
|
Legallais C, Kim D, Mihaila SM, Mihajlovic M, Figliuzzi M, Bonandrini B, Salerno S, Yousef Yengej FA, Rookmaaker MB, Sanchez Romero N, Sainz-Arnal P, Pereira U, Pasqua M, Gerritsen KGF, Verhaar MC, Remuzzi A, Baptista PM, De Bartolo L, Masereeuw R, Stamatialis D. Bioengineering Organs for Blood Detoxification. Adv Healthc Mater 2018; 7:e1800430. [PMID: 30230709 DOI: 10.1002/adhm.201800430] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2018] [Revised: 08/23/2018] [Indexed: 12/11/2022]
Abstract
For patients with severe kidney or liver failure the best solution is currently organ transplantation. However, not all patients are eligible for transplantation and due to limited organ availability, most patients are currently treated with therapies using artificial kidney and artificial liver devices. These therapies, despite their relative success in preserving the patients' life, have important limitations since they can only replace part of the natural kidney or liver functions. As blood detoxification (and other functions) in these highly perfused organs is achieved by specialized cells, it seems relevant to review the approaches leading to bioengineered organs fulfilling most of the native organ functions. There, the culture of cells of specific phenotypes on adapted scaffolds that can be perfused takes place. In this review paper, first the functions of kidney and liver organs are briefly described. Then artificial kidney/liver devices, bioartificial kidney devices, and bioartificial liver devices are focused on, as well as biohybrid constructs obtained by decellularization and recellularization of animal organs. For all organs, a thorough overview of the literature is given and the perspectives for their application in the clinic are discussed.
Collapse
Affiliation(s)
- Cécile Legallais
- UMR CNRS 7338 Biomechanics & Bioengineering; Université de technologie de Compiègne; Sorbonne Universités; 60203 Compiègne France
| | - Dooli Kim
- (Bio)artificial organs; Department of Biomaterials Science and Technology; Faculty of Science and Technology; TechMed Institute; University of Twente; P.O. Box 217 7500 AE Enschede The Netherlands
| | - Sylvia M. Mihaila
- Division of Pharmacology; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; Universiteitsweg 99 3584 CG Utrecht The Netherlands
- Department of Nephrology and Hypertension; University Medical Center Utrecht and Regenerative Medicine Utrecht; Utrecht University; Heidelberglaan 100 3584 CX Utrecht The Netherlands
| | - Milos Mihajlovic
- Division of Pharmacology; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; Universiteitsweg 99 3584 CG Utrecht The Netherlands
| | - Marina Figliuzzi
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri; via Stezzano 87 24126 Bergamo Italy
| | - Barbara Bonandrini
- Department of Chemistry; Materials and Chemical Engineering “Giulio Natta”; Politecnico di Milano; Piazza Leonardo da Vinci 32 20133 Milan Italy
| | - Simona Salerno
- Institute on Membrane Technology; National Research Council of Italy; ITM-CNR; Via Pietro BUCCI, Cubo 17C - 87036 Rende Italy
| | - Fjodor A. Yousef Yengej
- Department of Nephrology and Hypertension; University Medical Center Utrecht and Regenerative Medicine Utrecht; Utrecht University; Heidelberglaan 100 3584 CX Utrecht The Netherlands
| | - Maarten B. Rookmaaker
- Department of Nephrology and Hypertension; University Medical Center Utrecht and Regenerative Medicine Utrecht; Utrecht University; Heidelberglaan 100 3584 CX Utrecht The Netherlands
| | | | - Pilar Sainz-Arnal
- Instituto de Investigación Sanitaria de Aragón (IIS Aragon); 50009 Zaragoza Spain
- Instituto Aragonés de Ciencias de la Salud (IACS); 50009 Zaragoza Spain
| | - Ulysse Pereira
- UMR CNRS 7338 Biomechanics & Bioengineering; Université de technologie de Compiègne; Sorbonne Universités; 60203 Compiègne France
| | - Mattia Pasqua
- UMR CNRS 7338 Biomechanics & Bioengineering; Université de technologie de Compiègne; Sorbonne Universités; 60203 Compiègne France
| | - Karin G. F. Gerritsen
- Department of Nephrology and Hypertension; University Medical Center Utrecht and Regenerative Medicine Utrecht; Utrecht University; Heidelberglaan 100 3584 CX Utrecht The Netherlands
| | - Marianne C. Verhaar
- Department of Nephrology and Hypertension; University Medical Center Utrecht and Regenerative Medicine Utrecht; Utrecht University; Heidelberglaan 100 3584 CX Utrecht The Netherlands
| | - Andrea Remuzzi
- IRCCS-Istituto di Ricerche Farmacologiche Mario Negri; via Stezzano 87 24126 Bergamo Italy
- Department of Management; Information and Production Engineering; University of Bergamo; viale Marconi 5 24044 Dalmine Italy
| | - Pedro M. Baptista
- Instituto de Investigación Sanitaria de Aragón (IIS Aragon); 50009 Zaragoza Spain
- Department of Management; Information and Production Engineering; University of Bergamo; viale Marconi 5 24044 Dalmine Italy
- Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas (CIBERehd); 28029 Barcelona Spain
- Fundación ARAID; 50009 Zaragoza Spain
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz; 28040 Madrid Spain. Department of Biomedical and Aerospace Engineering; Universidad Carlos III de Madrid; 28911 Madrid Spain
| | - Loredana De Bartolo
- Institute on Membrane Technology; National Research Council of Italy; ITM-CNR; Via Pietro BUCCI, Cubo 17C - 87036 Rende Italy
| | - Rosalinde Masereeuw
- Division of Pharmacology; Utrecht Institute for Pharmaceutical Sciences; Utrecht University; Universiteitsweg 99 3584 CG Utrecht The Netherlands
| | - Dimitrios Stamatialis
- (Bio)artificial organs; Department of Biomaterials Science and Technology; Faculty of Science and Technology; TechMed Institute; University of Twente; P.O. Box 217 7500 AE Enschede The Netherlands
| |
Collapse
|
5
|
Pavlova LA, Pastukhov AV, Kopitsyna MN, Morozov AS, Bessonov IV, Smirnova SE, Bagnyukova DA, Davankov VA. Increasing selective bilirubin removal by hypercross-linked polystyrene hemosorbents. Russ Chem Bull 2018. [DOI: 10.1007/s11172-017-1963-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
6
|
Chen J, Han W, Su R, Chen J, Zong W, Wang Y, Wang W, Cheng G, Ou L, Yu Y. Non-ionic macroporous polystyrene adsorbents for removal of serum toxins in liver failure by hemoperfusion. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2016; 45:174-183. [DOI: 10.3109/21691401.2016.1138494] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Jian Chen
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Wenyan Han
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Rui Su
- Institute of Hepatopathy Medical Research, the Second People's Hospital, Tianjin, China
| | - Jie Chen
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Wenhui Zong
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Yue Wang
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Weichao Wang
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Guanghui Cheng
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Lailiang Ou
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| | - Yaoting Yu
- The Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, China
| |
Collapse
|
7
|
Peng Z, Yang Y, Luo J, Nie C, Ma L, Cheng C, Zhao C. Nanofibrous polymeric beads from aramid fibers for efficient bilirubin removal. Biomater Sci 2016; 4:1392-401. [DOI: 10.1039/c6bm00328a] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Polymer based hemoperfusion has been developed as an effective therapy to remove the extra bilirubin from patients.
Collapse
Affiliation(s)
- Zihang Peng
- College of Polymer Science and Engineering
- State Key Laboratory of Polymer Materials Engineering
- Sichuan University
- Chengdu 610065
- China
| | - Ye Yang
- College of Polymer Science and Engineering
- State Key Laboratory of Polymer Materials Engineering
- Sichuan University
- Chengdu 610065
- China
| | - Jiyue Luo
- College of Polymer Science and Engineering
- State Key Laboratory of Polymer Materials Engineering
- Sichuan University
- Chengdu 610065
- China
| | - Chuanxiong Nie
- College of Polymer Science and Engineering
- State Key Laboratory of Polymer Materials Engineering
- Sichuan University
- Chengdu 610065
- China
| | - Lang Ma
- College of Polymer Science and Engineering
- State Key Laboratory of Polymer Materials Engineering
- Sichuan University
- Chengdu 610065
- China
| | - Chong Cheng
- College of Polymer Science and Engineering
- State Key Laboratory of Polymer Materials Engineering
- Sichuan University
- Chengdu 610065
- China
| | - Changsheng Zhao
- College of Polymer Science and Engineering
- State Key Laboratory of Polymer Materials Engineering
- Sichuan University
- Chengdu 610065
- China
| |
Collapse
|
8
|
Wei H, Han L, Tang Y, Ren J, Zhao Z, Jia L. Highly flexible heparin-modified chitosan/graphene oxide hybrid hydrogel as a super bilirubin adsorbent with excellent hemocompatibility. J Mater Chem B 2015; 3:1646-1654. [DOI: 10.1039/c4tb01673d] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A highly flexible heparin-modified chitosan/graphene oxide hydrogel was prepared using lyophilization–neutralization–modification as a blood-compatible adsorbent for bilirubin removal.
Collapse
Affiliation(s)
- Houliang Wei
- School of Life Science and Biotechnology
- Dalian University of Technology
- Dalian 116023
- PR China
| | - Lulu Han
- School of Life Science and Biotechnology
- Dalian University of Technology
- Dalian 116023
- PR China
| | - Yongchao Tang
- Carbon Research Laboratory
- State Key Lab of Fine Chemicals
- School of Chemical Engineering
- Dalian University of Technology
- Dalian 116023
| | - Jun Ren
- School of Life Science and Biotechnology
- Dalian University of Technology
- Dalian 116023
- PR China
| | - Zongbin Zhao
- Carbon Research Laboratory
- State Key Lab of Fine Chemicals
- School of Chemical Engineering
- Dalian University of Technology
- Dalian 116023
| | - Lingyun Jia
- School of Life Science and Biotechnology
- Dalian University of Technology
- Dalian 116023
- PR China
| |
Collapse
|
9
|
Toyoda-Akui M, Yokomori H, Kaneko F, Shimizu Y, Takeuchi H, Tahara K, Motoori T, Ohbu M, Oda M, Hibi T. A case of drug-induced hepatic injury associated with sitagliptin. Intern Med 2011; 50:1015-20. [PMID: 21532224 DOI: 10.2169/internalmedicine.50.5057] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 58-year-old man with a 10-year history of type II diabetes mellitus presented with progressive jaundice that began three days before admission. Thorough history-taking revealed that the patient had started on a new medication, sitagliptin, one month previously for the treatment of diabetes mellitus. Laboratory investigations showed severe liver dysfunction. Ultrasonography detected no extrahepatic biliary duct dilatation or gallstones. Abdominal computed tomography excluded pancreatic and hepatic focal lesions. Liver function improved upon discontinuation of sitagliptin. Drugs are an important, often unrecognized, cause of acute liver injury. This report presents a rare case in which sitagliptin was responsible for acute hepatic damage. As demonstrated, a thorough drug history is helpful in any case of unexplained liver injury.
Collapse
Affiliation(s)
- Megumi Toyoda-Akui
- Department of Internal Medicine, Kitasato Medical Center Hospital, Kitasato University, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Ishihara T, Inoue S, Takagi Y, Shimomura T, Sagami Y, Katayama S, Eguchi Y, Watase K, Miyamoto M, Minakata T. Adverse Events in Therapeutic Apheresis: A Single Center Survey of Various Therapies. Ther Apher Dial 2010; 14:589-95. [DOI: 10.1111/j.1744-9987.2010.00832.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
KAMADA N, YONEYAMA K, TOGAWA Y, SUEHIRO K, SHINKAI H, YOKOTA M, MATSUDA K, ODA S, HIRASAWA H, MATSUE H. Toxic epidermal necrolysis with severe hyperbilirubinemia: Complete re-epithelialization after bilirubin reduction therapies. J Dermatol 2010; 37:534-6. [DOI: 10.1111/j.1346-8138.2009.00770.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Nishimura A, Umehara Y, Umehara M, Hakamada K, Narumi S, Toyoki Y, Yoshihara S, Sasaki M. Plasma Exchange-based Plasma Recycling Dialysis System as a Potential Platform for Artificial Liver Support. Artif Organs 2006; 30:629-33. [PMID: 16911318 DOI: 10.1111/j.1525-1594.2006.00273.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
We developed a plasma recycling dialysis (PRD) system based on plasma exchange (PE). In this system, rapid reduction of toxic substances and restitution of deficient essential substances are performed by PE, and subsequent blood purification is performed by dialysis between separated plasma recycled over a purification device and the patient's blood across the membrane of the plasma separator. This study was performed to demonstrate the safety and efficacy of this system. Hyperbilirubinemia was induced by ligating the bile duct in pigs, and 7 days later, only PE for 2 h (group PE) or PE for 2 h followed by PRD for 6 h (group PE + PRD) was performed. The separated plasma was recycled over anion-exchange resin through the extra fiber space of the plasma separator. The safety and efficacy of this system were evaluated based on the values of hemodynamic and laboratory parameters. Transfer from PE to PRD was completed in a few minutes. The hemodynamic status and blood cells counts were stable and hemolysis was not observed during the procedure. In the PE + PRD group, the concentrations of total bile acids continuously decreased (pretreatment, 155.5 +/- 40.6 microM; 2 h [end of PE], 76.1 +/- 14.4 microM; 8 h [end of PRD], 25.8 +/- 9.1 microM) and the value was significantly lower than in the PE group after 6 h. The total bilirubin also continuously decreased during PRD (pretreatment, 55.3 +/- 11.5 microM; 2 h [end of PE], 33.8 +/- 8.4 microM; 8 h [end of PRD], 18.6 +/- 7.7 microM) and was significantly lower than in the PE group after 4 h. No significant change was observed in other laboratory values. This PE-based PRD system allowed a swift transfer from PE to sorbent-based blood purification. The safety of this system was demonstrated and the removal of toxic substances was significant. This study confirmed the clinical utility of this system as a platform for artificial liver support.
Collapse
Affiliation(s)
- Akimasa Nishimura
- Department of Surgery, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Senf R, Klingel R, Kurz S, Tullius S, Sauer I, Frei U, Schindler R. Bilirubin-adsorption in 23 critically ill patients with liver failure. Int J Artif Organs 2005; 27:717-22. [PMID: 15478543 DOI: 10.1177/039139880402700810] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE Previous studies suggest that high levels of bilirubin exert cytotoxic, neurotoxic and encephalopathic effects that themselves may lead to further deterioration of liver function and multiorgan failure. Although extracorporeal BA is not a causal therapy, there are case reports of clinical benefits of BA. The present retrospective study investigated the clinical utility and effectiveness of BA in 23 patients with liver failure. METHODS Twenty-three patients (61+/-11 years) with excessive hyperbilirubinemia (>25 mg/dL) after liver transplantation (n=7), partial liver resection (n=12) and others (n=4) were treated with BA (3.6 liters plasma per BA, BR350, Asahi) and followed for 45+/-8 days. RESULTS A mean of 6.6 treatments (3-16) were performed per patient. On average, a single BA treatment reduced bilirubin-levels from 31+/-12 to 23.7+/-9 mg/dL (p<0.001). Levels of bile acid were reduced from 41.8+/-6 to 33.5+/-5 mg/dL. The 30-day mortality was 50%. BA was able to halt and stabilize the progressive increase in bilirubin levels in all patients. In contrast to survivors, non-survivors were characterized by a repeated rapid rise in bilirubin levels after cessation of BA treatment. CONCLUSIONS BA is able to stabilize or decrease bilirubin levels in patients with liver failure. Our experience suggests that BA is a safe and promising short-term treatment option for patients with acute deterioration of hepatic function.
Collapse
Affiliation(s)
- R Senf
- Department of Nephrology and Internal Intensive Care Medicine, Charité-Campus Virchow-Klinikum, Humboldt University, Berlin, Germany.
| | | | | | | | | | | | | |
Collapse
|
14
|
Kawagishi N, Ohkohchi N, Fujimori K, Orii T, Koyamada N, Kikuchi H, Satomi S. Experience with artificial liver support in 16 living related liver transplant recipients. THERAPEUTIC APHERESIS : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR APHERESIS AND THE JAPANESE SOCIETY FOR APHERESIS 2001; 5:7-11. [PMID: 11258616 DOI: 10.1046/j.1526-0968.2001.005001007.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
This study was a retrospective investigation about the indication and efficacy of artifical liver support for liver transplant recipients. Apheresis was performed in 16 of 41 patients subjected to living related liver transplantation (LRLTx) as articial liver support, including plasmapheresis (PP) in 13 cases, continuous hemodiafiltration (CHDF) in 7 cases, and plasma adsorption (PA) in 2 cases. One patient with cryptogenic liver cirrhosis was subjected to PP before the LRLTx, and the result was satisfactory. On the contrary, the results of PP and CHDF for graft, respiratory, or cardiac failure were not acceptable. Only 1 patient survived despite multiple organ failure. Both PP and PA for patients with hyperbilirubinemia were effective and improved their critical conditions. We conclude that apheresis for liver transplant patients is effective to treat hyperbilirubinemia, but it is not indicated for respiratory and cardiac failure nor for hepatic failure.
Collapse
Affiliation(s)
- N Kawagishi
- Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Sendai, Japan
| | | | | | | | | | | | | |
Collapse
|